Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Akira SezaiHisakuni SekinoSatoshi UnosawaMakoto TaokaShunji OsakaMasashi TanakaPublished in: Cardiovascular diabetology (2019)
Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes. Trial registration UMIN ( http://www.umin.ac.jp/ ), Study ID: UMIN000021239.
Keyphrases
- oxidative stress
- left ventricular
- type diabetes
- ejection fraction
- cardiovascular disease
- blood pressure
- clinical trial
- study protocol
- dna damage
- phase iii
- heart failure
- emergency department
- adipose tissue
- phase ii
- induced apoptosis
- skeletal muscle
- metabolic syndrome
- signaling pathway
- double blind
- electronic health record